Protalix Biotherapeutics Stock Performance
| PLX Stock | USD 2.06 0.02 0.96% |
The company holds a Beta of 1.42, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Protalix Biotherapeutics will likely underperform. At this point, Protalix Biotherapeutics has a negative expected return of -0.18%. Please make sure to check Protalix Biotherapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Protalix Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Protalix Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's essential indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 23.6 M | |
| Total Cashflows From Investing Activities | 4.2 M |
Protalix Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 237.00 in Protalix Biotherapeutics on October 29, 2025 and sell it today you would lose (31.00) from holding Protalix Biotherapeutics or give up 13.08% of portfolio value over 90 days. Protalix Biotherapeutics is generating negative expected returns assuming volatility of 3.2767% on return distribution over 90 days investment horizon. In other words, 29% of stocks are less volatile than Protalix, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Protalix Biotherapeutics Target Price Odds to finish over Current Price
The tendency of Protalix Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.06 | 90 days | 2.06 | about 26.79 |
Based on a normal probability distribution, the odds of Protalix Biotherapeutics to move above the current price in 90 days from now is about 26.79 (This Protalix Biotherapeutics probability density function shows the probability of Protalix Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon the stock has the beta coefficient of 1.42 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Protalix Biotherapeutics will likely underperform. Additionally Protalix Biotherapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Protalix Biotherapeutics Price Density |
| Price |
Predictive Modules for Protalix Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Protalix Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Protalix Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Protalix Biotherapeutics is not an exception. The market had few large corrections towards the Protalix Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Protalix Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Protalix Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.24 | |
β | Beta against Dow Jones | 1.42 | |
σ | Overall volatility | 0.21 | |
Ir | Information ratio | -0.06 |
Protalix Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Protalix Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Protalix Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Protalix Biotherapeutics generated a negative expected return over the last 90 days | |
| Protalix Biotherapeutics has high historical volatility and very poor performance | |
| Latest headline from finance.yahoo.com: With 73 percent ownership, First Internet Bancorp boasts of strong institutional backing |
Protalix Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Protalix Stock often depends not only on the future outlook of the current and potential Protalix Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protalix Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 81.1 M | |
| Cash And Short Term Investments | 34.8 M |
Protalix Biotherapeutics Fundamentals Growth
Protalix Stock prices reflect investors' perceptions of the future prospects and financial health of Protalix Biotherapeutics, and Protalix Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protalix Stock performance.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0553 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.12 % | |||
| Current Valuation | 146.08 M | |||
| Shares Outstanding | 80.42 M | |||
| Price To Earning | (1.23) X | |||
| Price To Book | 3.16 X | |||
| Price To Sales | 2.71 X | |||
| Revenue | 53.4 M | |||
| EBITDA | 6.52 M | |||
| Cash And Equivalents | 19.76 M | |||
| Cash Per Share | 0.41 X | |||
| Total Debt | 5.53 M | |||
| Book Value Per Share | 0.66 X | |||
| Cash Flow From Operations | 8.67 M | |||
| Earnings Per Share | 0.08 X | |||
| Total Asset | 73.42 M | |||
| Retained Earnings | (378.39 M) | |||
| Current Asset | 59.65 M | |||
| Current Liabilities | 10.33 M | |||
About Protalix Biotherapeutics Performance
Evaluating Protalix Biotherapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Protalix Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protalix Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company was founded in 1993 and is based in Hackensack, New Jersey. Protalix Biotherapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 202 people.Things to note about Protalix Biotherapeutics performance evaluation
Checking the ongoing alerts about Protalix Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protalix Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protalix Biotherapeutics generated a negative expected return over the last 90 days | |
| Protalix Biotherapeutics has high historical volatility and very poor performance | |
| Latest headline from finance.yahoo.com: With 73 percent ownership, First Internet Bancorp boasts of strong institutional backing |
- Analyzing Protalix Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protalix Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protalix Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protalix Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protalix Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protalix Biotherapeutics' stock. These opinions can provide insight into Protalix Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.